Epizyme, Inc.
Index- P/E- EPS (ttm)-2.14 Insider Own0.50% Shs Outstand144.20M Perf Week-3.51%
Market Cap82.23M Forward P/E- EPS next Y-1.14 Insider Trans- Shs Float123.98M Perf Month-31.21%
Income-236.40M PEG- EPS next Q-0.34 Inst Own93.20% Short Float7.62% Perf Quarter-68.96%
Sales38.50M P/S2.14 EPS this Y-6.60% Inst Trans61.86% Short Ratio4.33 Perf Half Y-86.80%
Book/sh-0.17 P/B- EPS next Y23.70% ROA-73.50% Target Price5.92 Perf Year-94.32%
Cash/sh1.18 P/C0.41 EPS next 5Y38.00% ROE- 52W Range0.44 - 9.86 Perf YTD-80.63%
Dividend- P/FCF- EPS past 5Y-4.90% ROI-135.80% 52W High-95.09% Beta1.30
Dividend %- Quick Ratio5.80 Sales past 5Y36.10% Gross Margin73.30% 52W Low10.04% ATR0.09
Employees250 Current Ratio5.90 Sales Q/Q14.50% Oper. Margin- RSI (14)32.93 Volatility15.58% 15.28%
OptionableYes Debt/Eq- EPS Q/Q44.20% Profit Margin- Rel Volume0.48 Prev Close0.51
ShortableYes LT Debt/Eq- EarningsMay 10 BMO Payout- Avg Volume2.18M Price0.48
Recom2.00 SMA20-21.06% SMA50-45.22% SMA200-83.50% Volume1,530,210 Change-5.10%
May-07-21Upgrade SVB Leerink Mkt Perform → Outperform $12 → $16
Apr-23-21Resumed Cowen Outperform $14
Mar-31-21Initiated Credit Suisse Outperform $13
Feb-25-21Downgrade Morgan Stanley Overweight → Equal-Weight $14
Dec-21-20Downgrade Jefferies Buy → Hold $14
Apr-01-20Downgrade Oppenheimer Outperform → Perform
Mar-04-20Initiated Barclays Overweight $33
Feb-25-20Reiterated H.C. Wainwright Buy $25 → $36
Jan-24-20Downgrade SVB Leerink Outperform → Mkt Perform
Dec-06-19Upgrade Morgan Stanley Equal-Weight → Overweight
May-30-19Resumed Citigroup Buy
Jan-07-19Upgrade Leerink Partners Mkt Perform → Outperform
Sep-07-18Resumed Morgan Stanley Equal-Weight
Jul-03-18Downgrade Leerink Partners Outperform → Mkt Perform
Jan-24-18Resumed Jefferies Buy $25
Jan-10-18Initiated Morgan Stanley Overweight $20
Nov-02-17Downgrade RBC Capital Mkts Outperform → Sector Perform $20 → $16
Sep-20-17Initiated Jefferies Buy $23
May-10-17Resumed RBC Capital Mkts Outperform $19 → $20
Apr-13-17Initiated Oppenheimer Outperform
May-17-22 07:00AM  
May-11-22 02:28PM  
May-10-22 08:15AM  
May-09-22 06:25PM  
May-03-22 12:00PM  
Apr-19-22 12:23PM  
Apr-14-22 10:06AM  
Apr-06-22 07:00AM  
Mar-31-22 11:30AM  
Mar-17-22 09:47AM  
Mar-16-22 12:00PM  
Mar-15-22 07:00AM  
Mar-02-22 11:22AM  
Mar-01-22 09:05AM  
Feb-22-22 07:00AM  
Feb-17-22 08:40AM  
Feb-15-22 03:01PM  
Feb-03-22 03:25PM  
Feb-01-22 10:00AM  
Jan-28-22 03:36PM  
Jan-27-22 06:27PM  
Jan-26-22 04:01PM  
Jan-10-22 07:00AM  
Jan-07-22 01:38PM  
Dec-12-21 09:00AM  
Dec-11-21 09:00AM  
Dec-02-21 06:30AM  
Nov-18-21 06:30AM  
Nov-12-21 08:00AM  
Nov-10-21 11:03AM  
Nov-09-21 03:30PM  
Nov-05-21 07:00AM  
Nov-04-21 06:30AM  
Nov-02-21 06:30AM  
Nov-01-21 08:00AM  
Oct-29-21 03:00PM  
Oct-23-21 06:08AM  
Oct-14-21 09:14AM  
Oct-07-21 07:00AM  
Sep-14-21 06:30AM  
Sep-08-21 11:30AM  
Aug-20-21 08:00AM  
Aug-10-21 03:40PM  
Aug-09-21 06:30PM  
Aug-08-21 08:00PM  
Aug-03-21 04:01PM  
Jul-27-21 06:48PM  
Jul-02-21 08:41AM  
Jun-28-21 04:15AM  
Jun-16-21 06:30AM  
Jun-14-21 12:59PM  
May-25-21 06:30AM  
May-12-21 04:01PM  
May-07-21 05:30PM  
May-06-21 08:05AM  
Apr-29-21 06:30AM  
Apr-01-21 12:13PM  
Mar-25-21 11:30AM  
Mar-02-21 12:00PM  
Feb-28-21 01:34AM  
Feb-25-21 10:03AM  
Feb-24-21 06:30AM  
Feb-23-21 08:00PM  
Feb-20-21 09:36AM  
Feb-16-21 06:30AM  
Jan-25-21 07:52AM  
Dec-18-20 02:43PM  
Dec-06-20 11:30AM  
Nov-29-20 12:30PM  
Nov-16-20 05:16AM  
Nov-15-20 11:16PM  
Nov-13-20 12:56PM  
Nov-11-20 04:05PM  
Nov-10-20 05:50AM  
Nov-09-20 10:16AM  
Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kutok JefferyChief Scientific OfficerApr 11Sale0.902,7412,46794,563Apr 13 05:49 PM
Beaulieu JosephCorporate ControllerFeb 07Sale1.5022233328,632Feb 09 05:43 PM
Agarwal ShefaliSee RemarksFeb 07Sale1.501,0581,587156,385Feb 09 05:40 PM
Beaulieu JosephCorporate ControllerFeb 02Sale1.3768794128,854Feb 04 04:15 PM
Agarwal ShefaliSee RemarksFeb 02Sale1.372,6393,615157,443Feb 04 04:15 PM
Kutok JefferyChief Scientific OfficerFeb 02Sale1.372,5563,50297,304Feb 04 04:15 PM
Legorreta Pablo G.DirectorJan 31Buy1.5022,666,66734,000,00031,833,334Feb 01 04:17 PM
Agarwal ShefaliSee RemarksJan 26Sale2.022,9225,902160,082Jan 28 04:15 PM
Agarwal ShefaliSee RemarksDec 06Sale2.931,7805,215163,004Dec 07 07:03 PM